Anna Nowogrodzki is a science and tech journalist whose writing appears in Nature, National Geographic, Smithsonian, Neo.Life, MIT Technology Review, and other publications. She is based in the Boston area.
Panelists at the World Medical Innovation Forum last week in Boston agreed that AI can bend the cost curve and improve access but the right incentives - such as those relating to value-based care - will be needed.
While it may not be possible for clinical trials to go completely virtual with AI, there are big cost and efficiency advantages to applying artificial intelligence to them.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Here's what is preventing biosimilars, which are growing in importance, from being more widely available in the U.S.